Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and90Y-labeled 1, 4, 7, 10-tetraazacyclododecane-N, N′, N′, N‴-tetraacetic acid (DOTA)-biotin

Cancer Research

Volumn 62, Issue 20, 2002, Pages 5755-5760

  Yao, Zhengsheng ^a   Zhang, Meili ^b   Axworthy, Donald B ^c   Wong, Karen J ^a   Garmestani, Kayhan ^b   Park, Luke ^a   Park, Chang W ^a   Mallett, Robert W ^c   Theodore, Louis J ^c   Yau, Eric K ^c   Waldmann, Thomas A ^b   Brechbiel, Martin W ^b   Paik, Chang H ^a   Pastan, Ira ^b   Carrasquillo, Jorge A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Poniard Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ANTIBODY CONJUGATE; BIOTIN; STREPTAVIDIN; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD GROUP LEWIS SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; DRUG TUMOR LEVEL; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RADIOIMMUNOTHERAPY; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOTIN; CARCINOMA, SQUAMOUS CELL; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNOCONJUGATES; INDIUM RADIOISOTOPES; MICE; MICE, NUDE; ORGANOMETALLIC COMPOUNDS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; STREPTAVIDIN; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS; YTTERBIUM;

EID: 0037108878     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Goldenberg, D. M. Targeted therapy of cancer with radiolabeled antibodies. J. Nucl. Med., 43: 693-713, 2002
2. Jain, R. K. Barriers to drug-delivery in solid tumors. Sci. Am., 271: 58-65, 1994
3. Saga, T., Neumann, R. D., Heya, T., Sato, J., Kinuya, S., Le, N., Paik, C. H., and Weinstein, J. N. Targeting cancer micrometastases with monoclonal-antibodies-a binding-site barrier. Proc. Natl. Acad. Sci. USA, 92: 8999, 1995
4. Goodwin, D. A. New methods for localizing infection: A role for avidin-biotin? J. Nucl. Med., 33: 1816-1818, 1992
5. Paganelli, G., Magnani, P., Zito, F., Villa, E., Sudati, F., Lopalco, L., Rossetti, C., Malcovati, M., Chiolerio, F., Seccamani, E., and et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res. 51: 5960-5966, 1991
6. Le Doussal, J. M., Barber, J., and Delaage, M. Bispecific-antibody-mediated targeting of radiolabeled bivalent haptens: Theoretical, experimental and clinical results. Int. J. Cancer (Suppl.), 7: 58-62, 1992
7. Green, N. M. Avidin. Adv. Protein Chem., 29: 85-133, 1975
8. Knox, S. J., Goris, M. L., Tempero, M., Weiden, P. L., Gentner, L., Breitz, H., Adams, G. P., Axworthy, D., Gaffigan, S., Bryan, K., Fisher, D. R., Colcher, D., Horak, I. D., and Weiner, L. M. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin. Cancer Res., 6: 406-414, 2000
9. Breitz, H. B., Weiden, P. L., Beaumier, P. L., Axworthy, D. B., Seller, C., Su, F. M., Graves, S., Bryan, K., and Reno, J. M. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. J. Nucl. Med., 41: 131-140, 2000
10. Axworthy, D. B., Reno, J. M., Hylarides, M. D., Mallett, R. W., Theodore, L. J., Gustavson, L. M., Su, F., Hobson, L. J., Beaumier, P. L., and Fritzberg, A. R. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl. Acad. Sci. USA. 97: 1802-1807, 2000
11. Pastan, I., Lovelace, E. T., Gallo, M. G., Rutherford, A. V., Magnani, J. L., and Willingham, M. C. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res., 51: 3781-3787, 1991
12. Pai-Scherf, L. H., Carrasquillo, J. A., Paik, C., Gansow, O., Whatley, M., Pearson, D., Webber, K., Hamilton, M., Allegra, C., Brechbiel, M., Willingham, M. C., and Pastan, I. Imaging and phase I study of 111In- and 90Y-labeled anti-LewisY monoclonal antibody B3. Clin. Cancer Res., 6: 1720-1730, 2000
13. Axworthy, D., Theodore, L. J., Gustavson, L. M., and Reno, J. M. Biotinidase-resistant biotin DOTA conjugates. United States Patent 5608060, 1997
14. Theodore, L. J., and Axworthy, D. B. Cluster Clearing Agents. PCT Application Int'l. Publication Number WO 97/46098, 1997
15. Wilbur, D. S., Hadley, S. W., Hylarides, M. D., Abrams, P. G., Beaumier, P. A., Morgan, A. C., Reno, J. M., and Fritzberg, A. R. Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer. J. Nucl. Med., 30: 216-226, 1989
16. Camera, L., Kinuya, S., Pai, L. H., Garmestani, K., Brechbiel, M. W., Gansow, O. A., Paik, C. H., Pastan, I., and Carrasquillo, J. A. Preclinical evaluation of 111In-labeled B3 monoclonal antibody: Biodistribution and imaging studies in nude mice bearing human epidermoid carcinoma xenografts. Cancer Res., 53: 2834-2839, 1993
17. Loevinger, R., and Berman, M. Calculating the Absorbed Dose from Biologically Distributed Radionuclides. New York: The Society of Nuclear Medicine, 1976
18. Stabin, M. G. MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine. J. Nucl. Med., 37: 538-546, 1996
19. Queen, C., Schneider, W. P., Selick, H. E., Payne, P. W., Landolfi, N. F., Duncan, J. F., Avdalovic, N. M., Levitt, M., Junghans, R. P., and Waldmann, T. A. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA, 86: 10029-10033, 1989
20. DeNardo, G. L., Kroger, L. A., DeNardo, S. J., Miers, L. A., Salako, Q., Kukis, D. L., Fand, I., Shen, S., Renn, O., and Meares, C. F. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-1T-BAD conjugated monoclonal antibody (BrE-3). Cancer (Phila), 73: 1012-1022, 1994